2004年深圳市重点医学专科中期评估分析

来源 :中华医学科研管理杂志 | 被引量 : 0次 | 上传用户:pjq521
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
目的了解深圳市重点医学专科中期建设情况并据此制订下一步的发展战略目标。方法根据《深圳市重点医学专科(实验室)评估指标体系(试行)》(该体系有19个Ⅱ级指标,总分值1 000分),分别从学科管理、人才建设、学科影响力、科技优势、教学培训、学科条件和医疗质量7个方面对已建设了2年的34个深圳市重点医学专科和实验室进行了中期评估。结果得分在700以上(A组)、600~699分(B组)、500~599分(C组)、400~499分(D组)及400分以下(E组)的重点医学专科分别为2个、12个、15个、4个和1个;其中,A组和B组的重点医学专科取得了满意的建设结果,但D组和E组没有达标,C组还需进行整改,有望在后半个建设周期内达标。结论按上述指标体系对现有的重点医学专科建设进行中期评估是可行的。评估结果可以为重点医学专科发展战略目标的制订提供科学的指导意见。 Objective To understand the medium-term construction of key medical specialties in Shenzhen and to formulate the next-step strategic goals for development. Methods According to “Shenzhen Key Medical Specialist (Laboratory) Evaluation Index System (Trial)” (the system has 19 Level II indicators with a total score of 1 000 points), from discipline management, personnel development, subject influence, technology Advantages, teaching and training, academic conditions, and medical care quality We conducted mid-term evaluations on 34 key medical specialties and laboratories in Shenzhen that have been under construction for two years. The key medical specialties with scores above 700 (Group A), 600 to 699 (Group B), 500 to 599 (Group C), 400 to 499 (Group D) and 400 (Group E) were 2, 12, 15, 15, and 1; among them, the key medical specialties of group A and group B have achieved satisfactory results, but group D and group E have not met the standards, and group C needs to be rectified. In the second half of the construction period to achieve compliance. Conclusion According to the above index system, it is feasible to conduct mid-term evaluation of the existing key medical specialties. The assessment results can provide scientific guidance for the development of strategic objectives for key medical specialists.
其他文献
长期以来,农村卫生资源短缺,许多乡镇卫生院设备陈旧、人员老化,病员稀少,医务人员收入普遍较低,而城市大中型医院人才多,设备先进,但众多农村重病患者进城看病不但不便、且花销较大,"因病致贫"、"因病返贫"成为农村居民贫困的原因之
目的:研究银杏叶提取物(extract of ginkgo biloba,EGB)对转化生长因子β1(transforming growth factor-β1 TGF-β1)诱导的人肾小管上皮细胞HK2(human tubular epithelial c